🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Walvax Biotechnology Co., Ltd. (SHE:300142)
China flag China · Delayed Price · Currency is CNY
10.00
-0.64 (-6.02%)
Nov 20, 2026, 3:04 PM CST

Walvax Biotechnology Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
906.871,3533,7644,3653,8733,443
Short-Term Investments
-311.84----
Cash & Short-Term Investments
906.871,6653,7644,3653,8733,443
Cash Growth
-46.06%-55.77%-13.77%12.68%12.49%75.54%
Accounts Receivable
1,7182,1452,4103,1013,5772,481
Other Receivables
93.0174.4258.8114.18416.13774.86
Receivables
1,8112,2202,4683,2153,9933,255
Inventory
618.47574.16752.591,035995.81873.59
Other Current Assets
602.4887.7682.22119.2186.25107.94
Total Current Assets
3,9394,5467,0678,7338,9487,680
Property, Plant & Equipment
3,9744,0324,0793,7683,1612,604
Long-Term Investments
647.21,3671,6381,0571,2921,491
Goodwill
33.6633.6633.6633.6633.6633.66
Other Intangible Assets
832.07831.431,0351,0861,167434.98
Long-Term Accounts Receivable
-3.677.27---
Long-Term Deferred Tax Assets
104.13110.81104.56103.44124.84168.01
Long-Term Deferred Charges
633.76586.4513.86473.48309.381,022
Other Long-Term Assets
277.98559.32246.62333.54300.2240.63
Total Assets
10,44212,07114,72415,58915,33613,674

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
1,1821,3681,5681,8051,8361,258
Accrued Expenses
37.41212.79549.81722.051,145754.71
Short-Term Debt
452.65163.43-320.2797.18310
Current Portion of Long-Term Debt
107.977.6638.988.79--
Current Portion of Leases
-11.477.8521.8823.354.6
Current Income Taxes Payable
17.942.71-14.1319.472.03
Current Unearned Revenue
30.8220.42106.18160.47192.9635.29
Other Current Liabilities
127.4150.6499.4151.25194.15870.61
Total Current Liabilities
1,9571,9372,3703,2043,5093,235
Long-Term Debt
836.26189.56433.34434.9314.24-
Long-Term Leases
7.3116.5211.7720.627.741.06
Long-Term Unearned Revenue
260.63276.77278.44423.33404.53344.3
Long-Term Deferred Tax Liabilities
13.0116.4255.9168.7190.9494.56
Other Long-Term Liabilities
83.297.86742.08--
Total Liabilities
3,1572,5343,2164,1944,3463,675

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
1,5991,5991,5991,6071,6071,601
Additional Paid-In Capital
1,9193,4144,5494,9004,9654,772
Retained Earnings
3,4163,2243,1102,9842,5801,895
Treasury Stock
----358.63-286.42-
Comprehensive Income & Other
-384.29171.28217.18217.18216.33
Total Common Equity
6,9348,6219,4309,3499,0848,484
Minority Interest
351.28915.42,0782,0461,9061,515
Shareholders' Equity
7,2859,53611,50811,39510,9909,999
Total Liabilities & Equity
10,44212,07114,72415,58915,33613,674

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
1,404388.63491.94806.42462.51315.67
Net Cash (Debt)
-497.311,2763,2723,5583,4113,128
Net Cash Growth
--61.00%-8.05%4.31%9.06%62.77%
Net Cash Per Share
-0.310.802.052.222.131.99
Filing Date Shares Outstanding
1,5991,5991,5991,5991,6011,601
Total Common Shares Outstanding
1,5991,5991,5991,5991,6011,601
Working Capital
1,9832,6094,6975,5295,4404,445
Book Value Per Share
4.345.395.905.855.675.30
Tangible Book Value
6,0687,7568,3618,2307,8838,016
Tangible Book Value Per Share
3.794.855.235.154.925.01
Buildings
-954.86953.95948.5767.91541.68
Machinery
-2,2232,1962,0931,5801,235
Construction In Progress
-2,2842,1141,6451,5091,527